Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Pancreatic cancer: moving forward

Michel Ducreux • 1 Oct 2019
ESMO 2019
Gastrointestinal Cancer Pancreatic Cancer Folfirinox Gemcitabine Nab-paclitaxel

Michel Ducreux, MD, PhD, Gustave Roussy Institute, Villejuif, France, describes where we are at with the treatment of pancreatic cancer, and what the future holds at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Michel Ducreux

1:40
Early diagnosis in advanced pancreatic cancer: how will we achieve this?
Michel Ducreux • 1 Oct 2019
1:31
Pancreatic Cancer: peri-operative precision
Michel Ducreux • 29 Sep 2019
1:58
Optimizing CRC and uHCC outcomes with TKIs
Michel Ducreux • 28 Sep 2019
2:04
Synergy of anti-androgenic agents and immune checkpoint inhibitors in HCC
Michel Ducreux • 9 Nov 2018

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals